Press-release for stocks publishing date 2021 - 06

Prices are updated after-hours

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $137.89 -0.94% 220K

| -2.7% | O: 0.21% H: 0.17% C: 0.12%
approval fda fda approval nivolumab

58%

42%

CSSE 4 | $0.3686 142.02% 76M

CZOO | $11.685 134.17% 7.6M

BOF | $1.93 64.96% 55M

AMST | $3.14 57.0% 59M

LICN | $0.7885 40.8% 11M

TROO | $1.51 38.53% 5.6M

MULN | News | $3.7 35.53% 6.4M

WHLM | $6.61 30.12% 400K

RILY | $27.91 28.5% 8.9M

RBBN 4 | $3.25 26.46% 1.5M

Save your searches and get alerts when important news are released.